Table 1.
High-frequency major MeSH terms from the included publications on vitamin D (n=76 125).
| No. | MeSH terms | Frequency n (%*) | Cumulative percentage (%) |
|---|---|---|---|
| 1 | Humans | 4094 (5.38) | 5.38 |
| 2 | Female | 2848 (3.74) | 9.12 |
| 3 | Male | 2459 (3.23) | 12.35 |
| 4 | Vitamin D/blood | 2087 (2.74) | 15.09 |
| 5 | Vitamin D/analogs and derivatives | 1613 (2.12) | 17.21 |
| 6 | Middle-aged | 1495 (1.96) | 19.17 |
| 7 | Adult | 1475 (1.94) | 21.11 |
| 8 | Aged | 1067 (1.40) | 22.51 |
| 9 | Vitamin D deficiency/blood | 903 (1.19) | 23.70 |
| 10 | Dietary supplements | 857 (1.13) | 24.83 |
| 11 | Animals | 834 (1.10) | 25.92 |
| 12 | Young adult | 644 (0.85) | 26.77 |
| 13 | Vitamin D/administration & dosage | 641 (0.84) | 27.61 |
| 14 | Adolescent | 563 (0.74) | 28.35 |
| 15 | Risk factors | 553 (0.73) | 29.07 |
| 16 | Vitamin D deficiency/epidemiology | 513 (0.67) | 29.75 |
| 17 | Cross-sectional studies | 499 (0.66) | 30.40 |
| 18 | Vitamin D deficiency/complications | 490 (0.64) | 31.05 |
| 19 | Vitamin D/therapeutic use | 481 (0.63) | 31.68 |
| 20 | Child | 437 (0.57) | 32.25 |
| 21 | Vitamin D/metabolism | 411 (0.54) | 32.79 |
| 22 | Vitamin D deficiency/drug therapy | 366 (0.48) | 33.27 |
| 23 | Biomarkers/blood | 360 (0.47) | 33.75 |
| 24 | Aged, 80 and over | 359 (0.47) | 34.22 |
| 25 | Prospective studies | 353 (0.46) | 34.68 |
| 26 | Vitamin D/pharmacology | 339 (0.45) | 35.13 |
| 27 | Treatment outcome | 323 (0.42) | 35.55 |
| 28 | Pregnancy | 317 (0.42) | 35.97 |
| 29 | Case-control studies | 315 (0.41) | 36.38 |
| 30 | Prevalence | 305 (0.40) | 36.78 |
| 31 | Child, preschool | 276 (0.36) | 37.15 |
| 32 | Cholecalciferol/administration and dosage | 269 (0.35) | 37.50 |
| 33 | Double-blind method | 268 (0.35) | 37.85 |
| 34 | Vitamin D Deficiency/diagnosis | 263 (0.35) | 38.20 |
| 35 | Seasons | 260 (0.34) | 38.54 |
| 36 | Receptors, calcitriol/metabolism | 259 (0.34) | 38.88 |
| 37 | Body mass index | 253 (0.33) | 39.21 |
| 38 | Parathyroid hormone/blood | 252 (0.33) | 39.54 |
| 39 | Calcifediol/blood | 246 (0.32) | 39.86 |
| 40 | Vitamins/therapeutic use | 244 (0.32) | 40.19 |
| 41 | Mice | 241 (0.32) | 40.50 |
| 42 | Calcitriol/pharmacology | 234 (0.31) | 40.81 |
| 43 | Infant | 230 (0.30) | 41.11 |
| 44 | Follow-up studies | 213 (0.28) | 41.39 |
| 45 | Cohort studies | 212 (0.28) | 41.67 |
| 46 | Vitamins/administration and dosage | 205 (0.27) | 41.94 |
| 47 | Receptors, calcitriol/genetics | 196 (0.26) | 42.20 |
| 48 | Calcium/blood | 195 (0.26) | 42.45 |
| 49 | Dose-response relationship, drug | 189 (0.25) | 42.70 |
| 50 | Retrospective studies | 180 (0.24) | 42.94 |
| 51 | Time factors | 177 (0.23) | 43.17 |
| 52 | Cholecalciferol/therapeutic use | 172 (0.23) | 43.40 |
| 53 | Infant, newborn | 161 (0.21) | 43.61 |
| 54 | Sunlight | 155 (0.20) | 43.81 |
| 55 | Cholecalciferol/pharmacology | 152 (0.20) | 44.01 |
| 56 | Severity of Illness Index | 152 (0.20) | 44.21 |
| 57 | Vitamin D deficiency/prevention and control | 152 (0.20) | 44.41 |
| 58 | Nutritional status | 146 (0.19) | 44.60 |
| 59 | Rats | 142 (0.19) | 44.79 |
| 60 | Diet | 138 (0.18) | 44.97 |
| 61 | Logistic models | 132 (0.17) | 45.14 |
| 62 | Vitamin D | 131 (0.17) | 45.31 |
| 63 | Vitamins/pharmacology | 129 (0.17) | 45.48 |
| 64 | Surveys and Questionnaires | 127 (0.17) | 45.65 |
| 65 | Cells, cultured | 122 (0.16) | 45.81 |
| 66 | Calcitriol/analogs and derivatives | 121 (0.16) | 45.97 |
| 67 | Age factors | 119 (0.16) | 46.13 |
| 68 | Bone density | 115 (0.15) | 46.28 |
| 69 | Disease models, animal | 114 (0.15) | 46.43 |
| 70 | Cell line, tumor | 114 (0.15) | 46.58 |
| 71 | Vitamins/blood | 114 (0.15) | 46.73 |
| 72 | Randomized Controlled Trials as Topic | 114 (0.15) | 46.88 |
| 73 | Prognosis | 114 (0.15) | 47.03 |
| 74 | Polymorphism, single-nucleotide | 112 (0.15) | 47.17 |
| 75 | Incidence | 110 (0.14) | 47.32 |
| 76 | Vitamin D Deficiency/metabolism | 110 (0.14) | 47.46 |
| 77 | Odds ratio | 104 (0.14) | 47.60 |
| 78 | Vitamin D Deficiency/etiology | 102 (0.13) | 47.73 |
| 79 | Linear models | 101 (0.13) | 47.87 |
| 80 | Multivariate analysis | 101 (0.13) | 48.00 |
| 81 | Cell line | 98 (0.13) | 48.13 |
| 82 | Calcitriol/administration and dosage | 95 (0.12) | 48.25 |
| 83 | Calcitriol/therapeutic use | 94 (0.12) | 48.38 |
| 84 | Ultraviolet rays | 94 (0.12) | 48.50 |
| 85 | Sex factors | 94 (0.12) | 48.62 |
| 86 | Vitamin D Deficiency/physiopathology | 94 (0.12) | 48.75 |
| 87 | Insulin resistance | 92 (0.12) | 48.87 |
| 88 | Diabetes Mellitus, Type 2/blood | 92 (0.12) | 48.99 |
| 89 | Calcium/metabolism | 91 (0.12) | 49.11 |
| 90 | Bone Density/drug effects | 90 (0.12) | 49.23 |
*
Proportion of the frequency among 76 125 appearances.